Is Wegovy safe? What the trials and label show

What this guide covers

Wegovy (semaglutide 2.4 mg) is FDA-approved for weight management and even cut cardiovascular events in a large trial, but it carries real side effects and warnings. Here is the honest risk picture and who should avoid it. This is patient education, not a substitute for the prescriber who knows your case. Generic names sit next to brand names throughout: semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound).

Key points

• Approved, and unusually well studied for the heart. Wegovy is high-dose semaglutide, approved by the FDA in 2021 for weight management. It stands out from most weight drugs because a large trial called SELECT, in people with heart disease and obesity but not diabetes, showed it reduced the risk of heart attack, stroke, and cardiovascular death. That is a benefit few weight medications have ever demonstrated. So safe here is not just about the absence of harm; there is a documented cardiovascular upside for a specific group, alongside a known side-effect profile that is worth understanding before starting.
• The everyday side effects. The common problems are digestive: nausea, diarrhea, vomiting, constipation, and stomach pain, usually mild to moderate, worst early and after each dose step-up, and easing as the body adjusts. Fatigue and headaches show up too. The four-to-five-month dose escalation, from 0.25 mg up to 2.4 mg, is built specifically to keep these tolerable. Most people who quit Wegovy in the first months do so because of these gut effects rather than anything dangerous, which is why a slow climb and adjusting how you eat make such a difference.
• The serious label warnings. Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent studies, not confirmed in people, which rules it out for anyone with a history of medullary thyroid cancer or MEN 2. Other uncommon but serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and serious allergic reactions. The label also notes possible depression or suicidal thoughts to monitor for, and reports have linked semaglutide to a rare eye condition called NAION that can affect vision. Low blood sugar is mainly a risk when combined with insulin or a sulfonylurea.
• Who should not take it. Wegovy is not for people with a personal or family history of medullary thyroid cancer or MEN 2, and it is not recommended in pregnancy, where semaglutide should be stopped well before a planned conception because of its long half-life. A history of pancreatitis, gallbladder disease, severe gut conditions, or diabetic eye disease all warrant a careful prescriber conversation. Anyone with a history of depression or suicidal thoughts should have that on the table too, since the label asks for monitoring.
• Lowering the risk in practice. Most of Wegovy's safety comes down to how it is used. Sourcing it from a legitimate pharmacy rather than an unregulated seller matters, because counterfeit and compounded semaglutide have been tied to dosing errors and contamination. Titrating slowly, staying hydrated through any vomiting or diarrhea, keeping protein up, and flagging severe or unusual symptoms early all reduce the odds of the rare serious problems. Knowing the red flags, relentless abdominal pain, sudden vision change, or signs of an allergic reaction, means you act rather than wait.

Frequently asked questions